Skip to main
IKNA
IKNA logo

Ikena Oncology (IKNA) Stock Forecast & Price Target

Ikena Oncology (IKNA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Ikena Oncology Inc demonstrates a positive outlook due to favorable preclinical data for its product candidate IK-595, which compares well with existing RAF/MEK molecular glues and second-generation MEK inhibitors. Additionally, IK-595 has shown promising potential for synergistic effects with various anticancer agents, indicating its capability to enhance antitumor activity across multiple treatment scenarios. This innovation has the potential to address the limitations of current MAPK strategies, positioning the company for future clinical advancements in oncology.

Bears say

Ikena Oncology reported a net loss of $10.2 million, or $0.21 per share, for the third quarter of 2024, indicating ongoing financial challenges. The company faces significant risks related to the efficacy of its drug candidates in clinical trials, which may fail to deliver meaningful results, leading to potential setbacks in achieving regulatory approval. Additionally, delays in regulatory processes and increasing competition within the oncology sector could further jeopardize Ikena Oncology’s growth prospects and impact its stock negatively.

Ikena Oncology (IKNA) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ikena Oncology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ikena Oncology (IKNA) Forecast

Analysts have given Ikena Oncology (IKNA) a Buy based on their latest research and market trends.

According to 3 analysts, Ikena Oncology (IKNA) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ikena Oncology (IKNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.